FGF19 analogs, designed to mimic the natural ligand while avoiding its tumor‐promoting effects, have demonstrated anti‐fibrotic and anti‐tumor properties by suppressing BAs synthesis and modulating downstream signaling pathways. The gene discussed is FGF19; the disease is neoplasm.